|
Unreadable document.
|
— |
AR226-3349
|
bypgL2JoaJM6OjyQoRqyKVKq0 |
17 |
|
The document reports on a study conducted by DuPont to investigate the biotransformation of 14C-labeled 8-2 Telomer B Alcohol (C8F17CH2CH2OH), focusing on its biotransformability, transformation products, and pathways under specific experimental conditions.
|
— |
AR226-3350
|
ypZeNDD7kmZpRZqzmDzQXY7j6 |
2 |
|
The document presents results from a study on the uptake and depuration of PFOS in fish, detailing the experimental setup with continuous flow-through systems, test concentrations, and recovery measurements over a 14-day period.
|
— |
AR226-3351
|
15YKo8n19zJxynGQanEex33nq |
17 |
|
The document discusses the biodegradation of fluorotelomer-based polymers, specifically focusing on the transformation products of perfluorohexanoic acid (PFHA) and other unidentified metabolites, through a 90-day experimental study involving industrial sludge and various analytical methods.
|
— |
AR226-3353
|
GK6p0p7ZYvmqZKoobL7d8Mx8V |
13 |
|
The document reports on a soil-water partitioning study of the fluorotelomer intermediate 8-2 Telomer B Alcohol (8-2 TBA) conducted by the Telomer Research Program, revealing that over 90% of the compound partitions to soil and sediment within three hours, indicating its non-mobile to slightly mobile nature in the environment.
|
— |
AR226-3354
|
NGw6rQEqL5gn7jembR3g9EqpR |
32 |
|
The document details a study conducted by DuPont researchers to evaluate the effects of fluorotelomer products on bacterial growth, pollutant degradation, and microbial populations in activated sludge from a domestic sewage treatment plant.
|
— |
AR226-3356
|
2nLR35vrv0xBo2Qxonwo48nr |
2 |
|
The document discusses the development of an analytical methodology using LC/MS and LC/MS/MS for the determination of Telomer B Alcohols and selected perfluorinated acids in environmental matrices, highlighting their role as intermediates in the production of fluorosurfactants used in various consumer products.
|
— |
AR226-3357
|
LkjRXxZq9w9g0jqm7z3edO7Q |
3 |
|
This document reports on the measurement of vapor pressures for a series of fluorotelomer alcohols (FTOHs) by DuPont researchers, revealing that previously published vapor pressure data may significantly overestimate these values, which is crucial for understanding their environmental transport potential.
|
— |
AR226-3361
|
YjOyRvJmBo5qEjqNxVwRLRZ78 |
36 |
|
The document details a study conducted by DuPont researchers on the biotransformation of 14C-labeled fluorotelomer substances, specifically 8-2 TelomerB Alcohol, by soil microorganisms, highlighting the environmental fate of fluorinated chemicals such as PFOS and PFOA.
|
— |
AR226-3364
|
BRN2XOG236kob76MzOjNBLBgo |
2 |
|
Empty document.
|
— |
AR226-3369
|
wBOOa8Xya2xrd0g9Zj24jXmV |
2 |
|
The document reports on bacterial respiration inhibition studies conducted by DuPont on fluorotelomer-based products, finding that at a concentration of 1000 mg L^-1, these substances did not inhibit bacterial growth in activated sludge from municipal wastewater treatment facilities, with estimated EC50 values greater than 1000 mg L^-1.
|
— |
AR226-3368
|
evNKxLN4NEJyRyoZRmVVnLgRG |
3 |
|
The document discusses the atmospheric fate of perfluorinated aldehydes (PFALs) as degradation products of fluorotelomer alcohols (FTOHs) and examines their UV and IR absorption spectra, highlighting the potential role of photolysis in their removal and the implications for the presence of perfluorooctanoic acid (PFOA) and other perfluoroalkyl
|
— |
AR226-3370
|
6wjdooNodxmmpEDQGJqzpBma9 |
15 |
|
This document is a letter from Taft Stettinius & Hollister LLP to the EPA Docket Center regarding the submission of information to the IRIS and AR-226 databases for PFOA/PFOS in response to a notice issued by the EPA.
|
— |
AR226-3905
|
RjNq6xK3KzoM34eog6kxBLQ7X |
32 |
|
This document details a study comparing the bioexposure potential and blood kinetics of perfluorooctanoic acid (PFOA) and perfluorooctanyl sulfonate (PFOS) in male rats, revealing that PFOS has a significantly higher area under the curve (AUC) and a longer terminal half-life than PFOA.
|
— |
AR226-3378
|
zo3Kv9a1OBREEodjOq1kYR8ma |
12 |
|
The document discusses the development of a biologically based model to describe the kinetics of perfluorooctanoic acid (PFOA) by researchers at DuPont, highlighting its metabolic inertness, biopersistence in humans, and differences in clearance rates between male and female rats.
|
— |
AR226-3379
|
065vmzRppa2pKJ5VVw1b0L6Qm |
1 |
|
The study by Hinderliter et al. from DuPont investigates the relationship between repeated inhalation exposures to perfluorooctanoic acid (PFOA) and plasma PFOA concentrations in rats, finding that PFOA is rapidly absorbed into the blood and that elimination rates differ by sex, with females eliminating PFOA more efficiently than males.
|
— |
AR226-3380
|
gb6VyEdNpyXwJ6K4pGY67Lq5V |
1 |
|
The document reports on a study evaluating the subchronic, reproductive, and developmental toxicity of a fluoroalkylethyl ethoxylate surfactant in rats, finding a NOEL of 25 mg/kg/day for subchronic toxicity and noting adverse effects on fertility and pup viability at higher doses, with some effects being reversible after recovery.
|
— |
AR226-3384
|
YZOEdrp0KrRZLKnBadVBJJNk |
18 |
|
The document describes a study conducted by The DuPont Company to evaluate the absorption and persistence of various fluorinated chemicals, including perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), in rats, finding that PFOS had a significantly higher blood uptake compared to PFOA, indicating differences in bioaccumulation potential among the
|
— |
AR226-3386
|
ZBnrV6egyXydm05ZzLvgBx7bd |
1 |
|
The document reports on a 90-day gavage study conducted by DuPont on a fluoroalkylethanol mixture, revealing subchronic and reproductive toxicity in rats, including reduced body weights, dental lesions, elevated fluoride levels, increased liver and kidney weights, and decreased litter size at doses of 100 mg/kg/day and above.
|
— |
AR226-3387
|
99Jd8GG6MzXnk8QrN9VvKZN55 |
1 |
|
The document reports on a study conducted by DuPont Haskell Laboratory evaluating the subchronic, developmental, and reproductive toxicity of a fluoroalkylethyl phosphate surfactant in rats, finding adverse effects on body weights and liver health at high doses, with a NOEL of 10 mg/kg/day for females and 500 mg/kg/day for reproductive parameters.
|
— |
AR226-3385
|
ExxJzbao8GjrV8KDbKGRB76Nj |
18 |
|
The document reports on a study conducted by DuPont evaluating the subchronic toxicity and reproductive effects of a fluoroalkylethyl urethane polymer used as a carpet protectant, finding no mortality or reproductive effects but noting significant nasal lesions and thyroid hypertrophy in male and female rats at higher dosages, with a NOEL of 50 mg/kg/day for reproductive assessments.
|
— |
AR226-3388
|
oDJp2GD2vXpQXQnvKegZGrvv3 |
1 |
|
This document reports on a study conducted by DuPont evaluating the toxicity of a fluoroalkylethyl phosphate surfactant in male rats through dermal and inhalation routes, finding a NOEL of 10 mg/kg/day for dermal exposure and 0.2 mg/m3 for inhalation, with liver enzymes elevated at higher doses but no significant adverse effects observed.
|
— |
AR226-3390
|
zz9Lr0oZpOvLJMokZxY9VaKwm |
1 |
|
This document reports on a range-finding study assessing the repeated dose oral toxicity of 8-2 Telomer B Alcohol in rats, conducted by DuPont and other collaborators, which found that PFOA constituted approximately 85% of total plasma fluorine in males and led to significant weight changes at the highest dose, informing subsequent dosing for a 90-day toxicity study.
|
— |
AR226-3391
|
6RopMYbRy1M9QzMwJE9Ly8de4 |
1 |
|
This document reports on a range-finding study assessing the repeated dose oral toxicity of 8-2 Telomer B Alcohol in rats, revealing that PFOA constituted approximately 85% of total plasma fluorine in males, with significant weight changes observed at the highest dose, leading to the selection of doses for a subsequent 90-day oral toxicity study.
|
— |
AR226-3395
|
Yo6760w42G6ZK4OD8LRO19BO |
13 |
|
The document discusses the analysis of C-8 (PFOA) in blood samples from DuPont's Teflon E-shift workers, revealing significant discrepancies in results between two laboratories, Shell VGW and National Medical Services, prompting a decision to resample and analyze one individual's blood at both labs to resolve the issue.
|
— |
AR226-3398
|
gpMRQXpwxLExwBkqXVzNvvJN |
3 |
|
This document outlines a gas chromatographic method developed by E. I. du Pont de Nemours and Company for the determination of perfluorooctanoic acid (PFOA) and its salts in blood, capable of measuring concentrations as low as 0.01 µg/g.
|
— |
AR226-3397
|
9JrY7N3RD5yvD1XVngExXVnaR |
23 |
|
The document is a trip report summarizing a visit to the National Medical Services Laboratory to review their procedures and data for determining perfluorooctanoic acid (PFOA) in blood samples, concluding that the reported concentrations were below the level of quantitation and requesting improvements in future testing standards.
|
— |
AR226-3399
|
1Lo75EEGdKoJD0JbEbqZnQOo |
3 |
|
The document discusses the development and validation of a new analytical procedure for detecting perfluorooctanoic acid (PFOA) in blood, highlighting issues with the previous method's reporting limit and proposing a change in methodology to improve detection accuracy.
|
— |
AR226-3400
|
jBq5XzbObDvNQq9emvqZwOEJk |
9 |
|
The document is a trip report by Dr. Mary A. Kaiser from DuPont, discussing a visit to the National Medical Services Laboratory to investigate discrepancies in blood levels of perfluorooctanoic acid (PFOA) between 2000 and 2001, attributed to the introduction of a new analytical method for the 2001 samples.
|
— |
AR226-3402
|
v1J0drk11dn2Kpjz3vKaVXQLm |
4 |
|
The document outlines a procedure for extracting and analyzing perfluorooctanoic acid (PFOA) in plasma using gas chromatography-mass spectrometry (GC-MS), detailing the necessary devices, chemicals, and methods for accurate determination relevant to industrial and environmental medicine.
|
— |
AR226-3401
|
mB0Ygy4ZgpkQxXDpg54ek3nxB |
9 |
|
This document is a site manual for DuPont's PFOA screening, detailing instructions and supplies for sample collection and processing, including specific procedures to minimize contamination during the study.
|
— |
AR226-3403
|
RpVgGEagoN5Z64LbNLmqMdMME |
9 |
|
The document details the validation of bioanalytical methods for quantifying perfluorooctanoic acid (PFOA) in human serum, utilizing advanced liquid chromatography and mass spectrometry techniques to address measurement uncertainties.
|
— |
AR226-3405
|
4Jg4pqeDKB1XmgmJa70O52z4Q |
3 |
|
This document is a method validation report detailing the development of a sensitive and accurate analytical method by Advion BioSciences, Inc. for quantifying ammonium perfluorooctanoate (APFO), measured as the perfluorooctanoate anion (PFOA), in human serum samples using LC/MS/MS, achieving a lower limit of quantitation of 0.05
|
— |
AR226-3404
|
Em25Z151mBzq2MLNYpgvN3OYb |
56 |
|
The memo discusses a meeting between Du Pont and 3M regarding the measurement of organic fluorochemicals, specifically noting that blood concentrations of perfluorinated compounds among Du Pont employees are normal, with no adverse health effects found, and that a gas chromatographic method for detecting perfluorooctanoic acid (PFOA) in biological materials has been developed by 3M.
|
— |
AR226-3409
|
daapop62GKQD5Q5OXrqyZJZQG |
4 |
|
The document is a bioanalytical report detailing the quantitative determination of ammonium perfluorooctanoate (APFO), measured as the perfluorooctanoate anion (PFOA), in human serum samples from Study DW04 using a turbo ion spray LC/MS/MS method, with a lower limit of quantitation of 0.05 pg/mL and a precision of
|
— |
AR226-3406
|
858m5Q9dj39xeYkMaeZ22oQva |
20 |
|
This is a research report authored by Emily Decker, prepared for DuPont, detailing a method for analyzing perfluorooctanoic acid (PFOA) in serum using LCZMS/MS.
|
— |
AR226-3407
|
jgGwOpn1Y3Ko8YE9VJrqKOJR9 |
21 |
|
This document details the validation procedure for determining total fluorine in blood using the Wickbold Torch method combined with direct potentiometric detection, outlining the calibration and evaluation of fluoride ion-selective electrode performance.
|
— |
AR226-3408
|
QgMBjrk8REG4OQoaZZBXxo8R5 |
20 |
|
The document discusses findings related to organic fluorocompounds, specifically perfluorooctanoic acid (PFOA), in blood plasma of employees exposed to long-chain perfluorosurfactants supplied by 3M Company to Du Pont, noting elevated levels in exposed individuals compared to a control group, while indicating no adverse health effects and a slow decay rate of fluorine in urine.
|
— |
AR226-3410
|
VGmkDOdgVQD6kLqXbwNNnaZNK |
4 |
|
The document provides a chronological summary of reports on ammonium perfluorooctanoate (PFOA) from 3M and Du Pont, detailing various studies and findings related to organic fluorides in blood and their concentrations among different populations from 1978 to 1979.
|
— |
AR226-3411
|
OKyepqB3XwxQYgVmewbEy5p |
3 |
|
This document appears to be a data report from an unspecified laboratory detailing blood analysis results related to exposure at a workplace in Philadelphia, with measurements of various contaminants including FC-143.
|
— |
AR226-3412
|
Lgj6mz5ZJQajbZ3n4vajXv7E7 |
2 |
|
The document summarizes blood sample analysis for organic fluorides, including PFOA, from various operator groups at different production facilities, reporting a range of concentrations with the highest average found in process operators at the Washington Works site.
|
— |
AR226-3413
|
0Jev5anJX4DBpxBRazRNMQQOO |
2 |
|
The document presents analytical results for C-8 (PFOA) levels from various locations, indicating non-detectable (ND) levels and average concentrations across multiple sites, with the highest average found at Spruante (0.027 PPM).
|
— |
AR226-3414
|
6B3OexdoxBXo0XyRQkL2Xkowg |
2 |
|
The document discusses a 3M study revealing elevated organic fluorine levels in the blood plasma of employees involved in the manufacture of fluorosurfactants, indicating potential exposure sources and the initiation of a special medical program for current workers, while noting that the specific products implicated are not manufactured at the Chambers Works facility.
|
— |
AR226-3416
|
Z44q5O7zKaXaJJnoDqZZb4Grd |
2 |
|
The document is a correspondence from Haskell Laboratory for Toxicology discussing the retention of ammonium perfluorooctanoate (C-8) in the blood of Teflon workers, suggesting modifications to the interpretation of blood concentration data to better understand human exposure and elimination dynamics.
|
— |
AR226-3415
|
a478pJ5Jkj5R685doEEjj9OzN |
4 |
|
The document presents employee blood data on organic fluorine levels, specifically highlighting median and mean values for PFOA exposure among plant workers and control groups from various years, indicating significant variability in exposure levels.
|
— |
AR226-3417
|
ppr5RyyvYYQxyzvyVo8kDobgw |
3 |
|
The document presents analytical results of blood fluorine levels related to perfluorooctanoate (PFOA) in production building operators, showing a range of concentrations from 0 to 0.250 ppm with an overall mean of 0.049 ppm.
|
— |
AR226-3418
|
9JN64M0ORbJJdV68z1e2eGkye |
2 |
|
The document discusses the initial results of the C-8 surveillance project at Chambers Works, indicating that perfluorooctanoic acid (C-8) levels ranged from below detection to 61 ppb, with no significant differences among worker groups, emphasizing the need for further longitudinal sampling to understand exposure variations.
|
— |
AR226-3419
|
baQjVx0y2rgkRJgQq8Dg82086 |
2 |
|
The document is a draft letter from DuPont regarding a C8 medical surveillance program, informing participants that additional blood samples will be taken to analyze for perfluorooctanoate (PFOA) and total fluorine to assess potential exposure over the past year.
|
— |
AR226-3421
|
Zn828j49jwqg2Lo1y0EG8jm60 |
3 |
|
The document outlines plans for follow-up medical surveillance of employees who participated in a baseline study on perfluorooctanoic acid (PFOA) exposure, detailing the procedures and analyses to be conducted, including blood tests for PFOA levels.
|
— |
AR226-3420
|
n9kBjB99vNxqOML3B1B7OGQbR |
4 |
|
The document discusses the analytical results of C8 blood samples related to perfluorinated compounds, expressing concerns about the methodology and requesting further analysis from the lab.
|
— |
AR226-3422
|
0Jb19Rb8GRjz74LVORM0a2Jwn |
8 |
|
The document proposes a feasibility assessment for estimating exposure, biopersistence, and potential liver effects from workplace exposures to organofluorines, specifically ammonium perfluoro-octanoate (C-8), highlighting concerns about long-term health risks and slow elimination from the body.
|
— |
AR226-3423
|
MMMQMVb70KZ205jO2KOMMaw2z |
5 |
|
This document appears to be a summary of C-8 exposure data, including blood PPM levels over various years, prepared by DuPont de Nemours for internal review.
|
— |
AR226-3425
|
4vxB4pmZG6wwoG8eVKg8vyd7e |
2 |
|
The document reports on a blood serum monitoring study conducted by DuPont Company at Chambers Works, NJ, in September-October 2002, revealing that perfluorooctanoic acid (PFOA) concentrations in sampled individuals varied, with a mean concentration of 172 ppb across the entire cohort.
|
— |
AR226-3424
|
6RRQ8deM189d1JBDK1jzbeeyE |
15 |
|
The document discusses a February 1997 meeting regarding occupational health issues related to C-8 (PFOA) and C-9 emissions at Washington Works, highlighting high personal exposure levels and corrective actions taken to reduce exposure.
|
— |
AR226-3426
|
NEVzQxB8qwEDmqV9da5zyZ9mw |
3 |
|
This document reports on a C-8 (PFOA) blood monitoring program conducted in May for 38 employees at the Homo Polymers facility, indicating varying levels of C-8 exposure among different employee groups and confirming the reliability of results through cross-analysis between U.S. and German laboratories.
|
— |
AR226-3427
|
KGge8wg4QxkkmyNvzk7QgRjoQ |
14 |
|
The document details the analysis of perfluorooctanoate (PFOA) concentrations in blood samples collected by DuPont, with results indicating various levels of PFOA presence across different samples.
|
— |
AR226-3428
|
4vqE2BRL63Z6dGRKmv60Rrevx |
3 |
|
This document summarizes blood serum monitoring data for Perfluorooctanoic Acid (PFOA) from Fayetteville Works, showing concentrations from October 2002 and December 2003, with maximum levels reaching 2280 ppb in the latter sampling.
|
— |
AR226-3430
|
ppdZvEz8ygj6KN4QMwvp1KKya |
7 |
|
The document discusses blood test results for employees exposed to FC-143, a fluorosurfactant produced by 3M, indicating no significant exposure to organic fluorine despite detectable levels, with no adverse health effects reported.
|
— |
AR226-3431
|
e7Qg6r5bLx8vMeoM8p1nVeeGG |
3 |
|
This document contains analytical results from a gas chromatography precision study, detailing measurements of various spiked levels of FC-143 in blood samples, associated with ILC and PPD/S. Stafford.
|
— |
AR226-3432
|
gE3kw4X3G9d3EGQJdyp67pY6J |
2 |
|
Unreadable document.
|
— |
AR226-3434
|
x1xY5XLjxBy4jnnw3JKxON35y |
3 |
|
This document contains a summary of organic fluoride levels in blood samples, detailing various operators' exposure history and corresponding PPM values, but lacks a clear analytical report format.
|
— |
AR226-3433
|
GzZ76O68mLXmVMvnYqERaeqEm |
7 |
|
This document presents analytical results for C-8 levels in blood samples from current female employees at Washington Works, indicating an average concentration of 0.92 ppm with 53 samples exceeding 0.05 ppm.
|
— |
AR226-3435
|
RJXnvy2dpNZ7njBOXMYXNo9XV |
2 |
|
This document presents data on C-8 (PFOA) blood levels in females who were transferred out of Teflon production, showing a statistically significant average decrease of 15.3% in blood levels after leaving the facility.
|
— |
AR226-3436
|
LJddRBkp2yG9Kwpbzpk7J7GYX |
2 |
|
The document contains work histories of female employees at DuPont related to their exposure to organic fluorine levels, specifically in the context of Teflon production, with data arranged to show the correlation between exposure duration and fluorine levels.
|
— |
AR226-3437
|
qdJmaj2yKEm8ee8K9D0ergXkn |
3 |
|
This document discusses the retention and absorption of C-8 vapor (likely referring to perfluorooctanoic acid, PFOA) in the blood of employees exposed to it, estimating that approximately 4% is retained, with variations based on individual factors and airborne particle sizes, and highlights the need for further data to better understand its fate in the body.
|
— |
AR226-3439
|
kxB5GLeN9oMmRk9x5jqdjDQ0 |
4 |
|
The document outlines an authorization request for a study to assess worker exposure to measured serum perfluorinated octanoic acid anion during the manufacture of ammonium perfluorooctanoate (APFO) at DuPont's Fayetteville, NC facility.
|
— |
AR226-3429
|
K6e0DVkwKDJgB04p1D5Ja5yBQ |
86 |
|
The document reports on a study of blood C-8 (perfluorooctanoic acid, PFOA) levels among various employee groups in the TEFLON division, indicating a significant average decrease of 23% for FEP operators and 18% for Fine Powder operators from October 1981 to June 1982, with new employees accumulating C-8 at a lower rate
|
— |
AR226-3438
|
RpZo40XEOEM32EoL39k205ZKk |
10 |
|
The document discusses the retention of ammonium perfluorooctanoate (C-8) in the blood of Teflon employees, indicating that approximately 40% of inhaled C-8 vapor is retained in the blood, while a toxicologist's review suggests that about 47% is retained in the entire body, with both estimates showing that significantly less than 100% is retained
|
— |
AR226-3440
|
bBDv1jXqVwkKpmRMxzY9pmyJg |
3 |
|
Unreadable document.
|
— |
AR226-3442
|
Qg6Lvoe64DbaZ1NB6drwpwjxo |
2 |
|
The document reports a statistically significant drop in blood C-8 (PFOA) levels among TEFLON Fine Powder/Dispersion and FEP Operators, with 16 out of 22 and 14 out of 15 operators respectively showing decreases over a two-year period.
|
— |
AR226-3441
|
0q41zZmKJknde2gKd6GE3XgEd |
6 |
|
The document presents blood C-8 (PFOA) levels for employees of the WNQANSH-FILNUGOTROONPOWLOYRMKSERS Division, indicating varying average levels among different individuals tested between 1973 and 1983.
|
— |
AR226-3444
|
6Rqogeg3G8Dv09dLwZ9naBB2d |
4 |
|
This document presents blood sample results indicating that 16 out of 22 employees showed statistically significant decreases in C-8 (PFOA) levels, while 4 experienced increases, suggesting a potential impact of occupational exposure to PFOA.
|
— |
AR226-3445
|
gbpBRKr8MNNgjNeV3EYy5xQga |
3 |
|
The document presents blood sample results measuring C-8 (perfluorooctanoic acid, PFOA) levels in workers exposed to Teflon production, showing variations in blood concentrations over time and indicating changes in exposure levels.
|
— |
AR226-3443
|
0qMOen1Dna38pR7y9r42DZ74d |
5 |
|
The document presents a trend analysis of C-8 (likely PFOA) blood levels among various DuPont process operators from 1981 to 1986, indicating a gradual decline in blood concentration over the years.
|
— |
AR226-3447
|
8R23MjaOpvY7x6LLYQMgRyBLy |
2 |
|
The document reports on a study of blood C-8 (PFOA) levels among TEFLON Fine Powder/Dispersion and FEP Operators, indicating an overall drop in blood levels, with Fine Powder/Dispersion Operators experiencing an average decrease of 24% and FEP Operators a 12% decrease over the past 2 to 3 years.
|
— |
AR226-3446
|
zQq7m0GB8m32bmb3DNN4JY7Y6 |
6 |
|
This document presents blood analysis data for non-fluorocarbon exposure, detailing the number of individuals and average C-8 levels in blood over varying durations of time spent in the plant.
|
— |
AR226-3448
|
3N64DNkOqoqgjbabbDZoaZJQO |
2 |
|
Unreadable document.
|
— |
AR226-3449
|
emjMrbJgvO1Qd9QXyveQoe0ny |
3 |
|
The document summarizes a review of C-8 (PFOA) personnel air monitoring and blood data from Washington Works, indicating a correlation between air levels and blood levels, with high blood levels associated with skin exposure in certain jobs.
|
— |
AR226-3451
|
mG8a3o7Vnn6g9pEBnZKZYknO |
4 |
|
The document discusses a liver study conducted on Washington Works employees exposed to C-8 (PFOA), concluding that there is no evidence of occupationally related health problems among workers, despite some indications of elevated fluoride levels.
|
— |
AR226-3453
|
pBOBXnq8d92Rj5n7qQ2w7ENVa |
4 |
|
The document reviews personnel air monitoring and blood data related to C-8 (PFOA) exposure at Washington Works, demonstrating a correlation between air levels, skin exposure, and blood levels, with significant findings indicating that skin contact contributes to elevated blood levels.
|
— |
AR226-3452
|
63e24RgLa2pqjqdbKQqjDZdg |
8 |
|
The document is a summary of C-8 (PFOA) blood level data for employees and a retiree from DuPont, indicating that while some individuals showed increases in blood levels, the overall trend suggests a decrease, particularly for a retiree whose levels are estimated to decrease at a rate of 0.15 ppm per year.
|
— |
AR226-3450
|
MGzoVXXbVnwXg1LLJnpraa5Qx |
18 |
|
This document contains blood test results for C-8 (PFOA) levels from 3M and NMS, with various numerical values listed alongside control numbers.
|
— |
AR226-3454
|
kDoJoDbBL4Ver6N8p58Ej1aRB |
3 |
|
The memorandum reports on a voluntary blood testing program for C-8 (PFOA) conducted in 1997, where twelve individuals were tested with results ranging from 0.00 to 0.56 ppm, concluding that the findings do not warrant concern or action.
|
— |
AR226-3455
|
jxyVJ52qpRkG9nYZpjx5Nxm2 |
2 |
|
The document reports on a 1995 study of blood levels of ammonium perfluorooctanoate (C-8) among employees potentially exposed to the substance, indicating that no individuals had levels exceeding 5 ppm, with job-specific averages ranging from 0.5 to 3.5 ppm, and highlights the persistence of C-8 in the blood and the need for ongoing monitoring
|
— |
AR226-3456
|
N2mNvgRKz57bbkgKq1LO39DzQ |
2 |
|
The document discusses preliminary blood test results for C-8 (PFOA) levels among employees at DuPont's Washington Works, revealing that four individuals had levels exceeding 5 ppm, prompting an investigation into a cluster of high results among Granular Polykettle Operators.
|
— |
AR226-3457
|
4QQqV9RnLVOpgkqOOnZgZegpG |
3 |
|
The document presents blood test results for pensioners exposed to C-8 (PFOA) from DuPont, showing a decrease in blood concentration levels from 1995 to 2000, with an estimated half-life of about four years.
|
— |
AR226-3458
|
8RDbNRJxX3nJJpgvR1E7oVmxk |
3 |
|
This document appears to be a summary of blood levels of PFOA among various job classifications from 1989 to 2000, highlighting significant changes and limitations in the data analysis due to small sample sizes and employee job transfers.
|
— |
AR226-3459
|
8VgLdnV32VjJenZvvLrE27NQZ |
9 |
|
This document appears to be a list of individuals with advanced degrees in environmental science and chemistry, detailing their current positions and relevant research experience, particularly in the field of environmental fate and chemistry of fluorinated compounds.
|
— |
AR226-3918
|
Q2vBdKa0Nq0a1MLV8rKRwZ5k |
1 |
|
This document is a letter from Taft Stettinius & Hollister LLP to the EPA Docket Center regarding the submission to the IRIS and AR-226 Database for PFOA/PFOS, in response to a notice issued by the EPA in 2006.
|
— |
AR226-3920
|
2qpJxYBboqweaJeoZKVeNK0K6 |
21 |
|
This document is a letter from Deborah McCrea to the EPA Docket Center regarding the submission of information to the IRIS and AR-226 databases for PFOA and PFOS in response to a previous EPA notice.
|
— |
AR226-3923
|
jmjbQN2yXXBXQdO4JB85Dj5MN |
39 |
|
This document presents half-life results for various samples, detailing concentrations (PPM) and corresponding dates, along with calculated average half-lives and standard deviation.
|
— |
AR226-3462
|
8RXv4vJdyaJO0pg2Dka6QG9zB |
2 |
|
The document presents blood concentration data for perfluorooctanoic acid (PFOA) in employees from 1984 to 1985, showing average levels and variations across different job categories.
|
— |
AR226-3461
|
x11GorkVNk4wvvoNbJr4YaL81 |
2 |
|
The document presents blood sample analysis results for PFOA levels from employees, indicating an average concentration of 2.49 ppm with a maximum of 11.1 ppm.
|
— |
AR226-3463
|
4EqwmDBKDDnV71XRwkZ4ba9a |
2 |
|
Unreadable document.
|
— |
AR226-3464
|
jd0yMagkz7nYD67bo91r74QR |
2 |
|
The document discusses the presence of C-8 (PFOA) in the blood of DuPont workers, highlighting its persistence, the normal liver function of those affected, and the ongoing voluntary blood testing program to monitor exposure levels and address concerns raised by previous data reviews.
|
— |
AR226-3465
|
6B34MLyGDE4DBaQV8awxYoMyE |
11 |
|
In May 1978, 3M informed Du Pont of the presence of organic fluorocompounds, including PFOA, in the blood of employees exposed to fluorosurfactants, prompting Chambers Works to initiate a program to assess exposure levels and health effects, which found that while employee blood levels were slightly elevated compared to a control group, they remained below 1 ppm and no adverse
|
— |
AR226-3467
|
e1vkQBeeJgjd35qNz9m6M5Q74 |
3 |
|
The document is a technical report from E.I. DuPont de Nemours & Company detailing a study on the kinetics of sorption and elimination of perfluorinated surfactants, specifically perfluorooctanoic acid, in rat blood following inhalation exposure, indicating that the concentration of organic fluorine in blood increases with inhaled concentration and elimination follows first-order kinetics.
|
— |
AR226-3466
|
6RnRxLnNMNYY8z6wZOxR1bDQm |
29 |
|
The document presents results from a blood study of Chambers Works employees, indicating that their levels of organic fluorine, including PFOA, are within normal ranges and do not show elevated levels compared to a Wilmington control group.
|
— |
AR226-3469
|
wgZvQkqBpJL9BdaaOz9v86wVD |
6 |
|
The document reports on a study analyzing health data from employees exposed to a surfactant, indicating that the exposed group had significantly higher incidences of allergic, endocrine, metabolic, mental, and skin disorders, while the control group had more incidents of circulatory diseases, with abnormal liver function tests being higher but not statistically significant in the exposed group.
|
— |
AR226-3468
|
j79ExzgONQpmGOQB7vkBZxbp |
14 |
|
The document summarizes a 1978-79 study conducted by DuPont on organic fluorine levels in the blood of Chambers Works employees potentially exposed to fluorosurfactants, which included air monitoring and blood analysis to assess exposure and health effects.
|
— |
AR226-3470
|
K6LJp24Nw2z1w4DaYn5aZm102 |
2 |